| Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). | |
| | |
MedLine Citation:
|
PMID: 9598154 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Seventeen patients with CLL were treated with oral 2-chloro-2'-deoxyadenosine (cladribine, CdA, 10 mg/m2) on 3 consecutive days and the pharmacokinetic parameters of CdA in patient plasma and its intracellular nucleotides (CdAMP, CdATP) in circulating leukemic cells were studied after the last dose intake and up to 72 h thereafter. The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh. The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP. The AUC of CdATP in leukemic cells is lower than the AUC of CdAMP (median ratio 0.60). There was no correlation between cellular CdATP and plasma CdA concentrations or dCK activity. The clinical response was related to higher Cmax values for plasma CdA (p = 0.05) and higher products of dCK activity and CdA Cmax of plasma (p = 0.02). The activity of dCK alone was not related to the clinical outcome in this patient group. The results suggest that further steps in the mechanism of action of CdA beyond its bioactivation may be more important, e.g. the extent of DNA fragmentation or the ability of the leukemic cell to go into apoptosis, than the concentration of CdA nucleotides alone. |
| | |
Authors:
|
F Albertioni; S Lindemalm; S Eriksson; G Juliusson; J Liliemark |
Related Documents
:
|
2321644 - High fluoride exposure in hemodialysis patients. 995584 - Blood magnesium and the renal magnesium threshold in lichen-fed and fasted reindeer. 1563944 - Serum and salivary magnesium levels in migraine. results in a group of juvenile patients. 22964804 - Serum and urine boron and selenium levels in children with resistant epilepsy. 467354 - Azotemic renal osteodystrophy; clinical features and bone pathology. 6361234 - Endocrine responses to exogenous bombesin and gastrin releasing peptide in conscious ca... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Advances in experimental medicine and biology Volume: 431 ISSN: 0065-2598 ISO Abbreviation: Adv. Exp. Med. Biol. Publication Date: 1998 |
Date Detail:
|
Created Date: 1998-07-23 Completed Date: 1998-07-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0121103 Medline TA: Adv Exp Med Biol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 693-7 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Veterinary Medical Chemistry, Linköping, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenine Nucleotides
/
blood Adenosine Triphosphate / analogs & derivatives*, blood Antineoplastic Agents / blood, pharmacokinetics, therapeutic use* Cladribine / analogs & derivatives*, blood, pharmacokinetics, therapeutic use* Deoxycytidine Kinase / metabolism* Female Half-Life Humans Kinetics Leukemia, Lymphocytic, Chronic, B-Cell / blood, drug therapy*, enzymology Leukocytes, Mononuclear / metabolism Male Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adenine Nucleotides; 0/Antineoplastic Agents; 0/cladribine triphosphate; 4291-63-8/Cladribine; 56-65-5/Adenosine Triphosphate; EC 2.7.1.74/Deoxycytidine Kinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Measurement of mutation frequency at the HPRT locus in peripheral lymphocytes. Is this a good method...
Next Document: Metabolism of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of...